Charles J Kahi, MD | |
10300 N Illinois St Ste 1100, Carmel, IN 46290-1167 | |
(317) 944-0980 | |
Not Available |
Full Name | Charles J Kahi |
---|---|
Gender | Male |
Speciality | Gastroenterology |
Experience | 28 Years |
Location | 10300 N Illinois St Ste 1100, Carmel, Indiana |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225092752 | NPI | - | NPPES |
200484500 | Medicaid | IN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RG0100X | Internal Medicine - Gastroenterology | 01051245 (Indiana) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Indiana University Health | Indianapolis, IN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Medical Diagnostic Associates Inc | 3375446347 | 279 |
News Archive
More than 98 per cent of men who are circumcised can enjoy the same levels of sexual satisfaction and performance as men who are not, according to a study of nearly 4,500 males published in the January issue of the UK-based urology journal BJU International.
Are deficits in attention limited to those with attention-deficit/hyperactivity disorder (ADHD) or is there a spectrum of attention function in the general population?
InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.
Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.
› Verified 7 days ago
Entity Name | University Medical Diagnostic Associates Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1861441537 PECOS PAC ID: 3375446347 Enrollment ID: O20040202000510 |
News Archive
More than 98 per cent of men who are circumcised can enjoy the same levels of sexual satisfaction and performance as men who are not, according to a study of nearly 4,500 males published in the January issue of the UK-based urology journal BJU International.
Are deficits in attention limited to those with attention-deficit/hyperactivity disorder (ADHD) or is there a spectrum of attention function in the general population?
InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.
Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Charles J Kahi, MD 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Charles J Kahi, MD 10300 N Illinois St Ste 1100, Carmel, IN 46290-1167 Ph: (317) 944-0980 |
News Archive
More than 98 per cent of men who are circumcised can enjoy the same levels of sexual satisfaction and performance as men who are not, according to a study of nearly 4,500 males published in the January issue of the UK-based urology journal BJU International.
Are deficits in attention limited to those with attention-deficit/hyperactivity disorder (ADHD) or is there a spectrum of attention function in the general population?
InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.
UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.
Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.
› Verified 7 days ago
Dr. Shelagh Anne Fraser, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 12174 N Meridian St Ste 300, Carmel, IN 46032 Phone: 317-688-9000 Fax: 317-680-9900 | |
Shania Grace Mayer, PA-C Gastroenterology Medicare: Medicare Enrolled Practice Location: 10300 N Illinois St Ste 1100, Carmel, IN 46290 Phone: 317-944-0980 | |
Robert Mark Kinn, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 13806 Stone Dr, Carmel, IN 46032 Phone: 317-893-1900 | |
Olivia Ann Fondoble, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 13430 N Meridian St Ste 280, Carmel, IN 46032 Phone: 317-582-8030 | |
Dr. Peter Jerome Bustamante, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 13450 N Meridian St Ste 354, Carmel, IN 46032 Phone: 317-338-5100 | |
Thomas L Hutchinson, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 11725 Illinois Street, Suite 465, Carmel, IN 46032 Phone: 317-817-0010 Fax: 317-817-0012 | |
Chintan J Amin, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 11725 Illinois St Ste 325, Carmel, IN 46032 Phone: 317-688-5800 Fax: 317-688-5805 |